OasisLMS

This discussion reviews the late-breaking HRS 2026 study Total Fatal Adverse Events Following Atrial Fibrillation Ablation Reported in an FDA Mandatory Reporting System: A Matter of Concern? The TiFFANY Study, which examined fatal adverse event reports associated with atrial fibrillation ablation using data from the FDA MAUDE database. Faculty discuss the incidence and mechanisms of rare but serious complications across ablation technologies, including pulsed field ablation and thermal energy sources, and explore the implications for procedural safety, post-market surveillance, and clinical decision-making in AF ablation.

Join host Melissa E. Middeldorp, MPH, PhD and her esteemed guests Christopher F. Liu, MD, FHRS and James Freeman, MD, MPH, Msci for this late-breaking coverage from Heart Rhythm 2026 in Chicago!

• Describe the methodology and key findings of the TiFFANY study evaluating fatal adverse events following atrial fibrillation ablation.
• Compare reported safety signals and complication profiles among pulsed field ablation and traditional thermal ablation technologies.
• Assess the role and limitations of post-market adverse event databases in evaluating procedural safety and informing electrophysiology practice. 

Podcast Contributors

Melissa E. Middeldorp, MPH, PhD, FHRS
Christopher F. Liu, MD, FHRS
James Freeman, MD, MPH, Msci 

All relevant financial relationships have been mitigated.

Host and Contributor Disclosure(s):

D.C. Raja

P. Lim

Nothing to disclose.

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):

S. Sailor: No relevant financial relationships with ineligible companies to disclose.